|
|
Article: The year of the Biotechs: when dozens of tech players fell off the CE 100 growth index, these scrappy survivors gladly took the top spots. (Management).(Statistical Data Included)(Industry Overview)
- Article from:
- Chief Executive (U.S.)
- Article date:
- May 1, 2002
- Author:
CopyrightCOPYRIGHT 2002 Chief Executive Magazine. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
The storm may have passed, but the damage to shareholder value was done--and the companies who lost it paid the price on Chief Executive's 11th annual growth index, or the CE 100. Not all were wiped out, however. The market tidal wave that toppled scores of overvalued dot-coms, telecoms and B2B technology firms left in its wake a core group of surviving companies that managed to shore up investors, even as share prices fluctuated wildly.
Biotechnology and medical companies did that especially well--or at least with some consistency from January 1999 to December 2001--according to this year's list of top performers (see methodology, page 26). Seven of the top 10 ...